168 related articles for article (PubMed ID: 9726086)
21. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
22. Benefit-risk assessment of irinotecan in advanced colorectal cancer.
Glimelius B
Drug Saf; 2005; 28(5):417-33. PubMed ID: 15853443
[TBL] [Abstract][Full Text] [Related]
23. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
24. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
Khayat D; Gil-Delgado M; Antoine EC; Coeffic D; Benhammouda A; Grapin JP; Bastian G
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):64-7. PubMed ID: 9726094
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan in the first-line treatment of colorectal cancer.
Saltz LB
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
[TBL] [Abstract][Full Text] [Related]
26. [Recent advance in chemotherapy for advanced colorectal cancer].
Aiba K
Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
[TBL] [Abstract][Full Text] [Related]
27. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Gibbs P; Clingan PR; Ganju V; Strickland AH; Wong SS; Tebbutt NC; Underhill CR; Fox RM; Clavant SP; Leung J; Pho M; Brown TJ
Cancer Chemother Pharmacol; 2011 Jan; 67(1):153-63. PubMed ID: 20333384
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
Shimada Y; Rougier P; Pitot H
Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
[TBL] [Abstract][Full Text] [Related]
30. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Van Cutsem E; Peeters M
Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
[TBL] [Abstract][Full Text] [Related]
31. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.
Oostendorp LJ; Stalmeier PF; Pasker-de Jong PC; Van der Graaf WT; Ottevanger PB
Anticancer Drugs; 2010 Sep; 21(8):749-58. PubMed ID: 20616701
[TBL] [Abstract][Full Text] [Related]
32. CPT-11: an original spectrum of clinical activity.
Rothenberg ML
Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
[TBL] [Abstract][Full Text] [Related]
33. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Rougier P; Bugat R
Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
[TBL] [Abstract][Full Text] [Related]
34. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
Cunningham D
Eur J Cancer; 1996; 32A Suppl 3():S1-8. PubMed ID: 8943658
[TBL] [Abstract][Full Text] [Related]
35. New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice.
Stucky-Marshall L
Cancer Nurs; 1999 Jun; 22(3):212-9. PubMed ID: 10376382
[TBL] [Abstract][Full Text] [Related]
36. CPT-11 (irinotecan) in the treatment of colorectal cancer.
Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Oncologic Drugs Advisory Committee
Clin Colorectal Cancer; 2002 May; 2(1):8-10. PubMed ID: 12453328
[No Abstract] [Full Text] [Related]
38. Irinotecan (Campto) in the treatment of pancreatic cancer.
Pizzolato JF; Saltz LB
Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan/thalidomide in metastatic colorectal cancer.
Govindarajan R
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):23-6. PubMed ID: 12014864
[TBL] [Abstract][Full Text] [Related]
40. [CPT-11: new drug for metastatic colorectal cancer].
Barone C; Pozzo C; Cassano A
Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
